Q-omics provides the consensus-scored ATP5MC2P3 profile across patient tissues and cancer cell-line models. ATP5MC2P3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ATP5MC2P3 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, ATP5MC2P3 RNA expression shows 16,821 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where ATP5MC2P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP5MC2P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP5MC2P3 survival associations across molecular data types. ATP5MC2P3 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP5MC2P3 RNA expression–survival associations across cancer types. High ATP5MC2P3 expression shows unfavorable associations in UVM, THCA and MESO, but favorable associations in LUSC, ACC and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ATP5MC2P3 RNA expression.
This table summarizes ATP5MC2P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ATP5MC2P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP5MC2P3 shows lower tumor expression in THCA and READ and higher tumor expression in KIRC, COAD, HNSC and ESCA. The KIRC box plot shows higher ATP5MC2P3 RNA expression in tumor versus normal tissue (log2 FC = +0.106, t-test p < 0.001).
This table shows molecular features associated with ATP5MC2P3 in patient tissues and cancer cell lines. In patient samples, ATP5MC2P3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
